MCM
LEGN icon

Moore Capital Management’s Legend Biotech LEGN Stock Holding History

Moore Capital Management’s Portfolio LEGN Stock Details LEGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-25,000
Closed -$1.21M – 561
2023
Q1 		$1.21M Buy
25,000
+15,000
+150% +$734K 0.03% 279
2022
Q4 		$499K Buy
+10,000
New +$484K 0.01% 355

Other funds holding LEGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Moore Capital Management's LEGN Position: Q2 2023 in Review

Moore Capital Management sold out of Legend Biotech (LEGN) in Q2 2023, closing a stake of 25,000 shares — an estimated $1.21M sold.

Moore Capital Management first reported a position in LEGN in Q4 2022 and held it in 2 quarters. The position peaked at $1.21M in Q1 2023. 194 funds tracked by Wall St. Rank hold LEGN as of Q2 2023.

  • Moore Capital Management reported no remaining Legend Biotech position as of Q2 2023 after selling out during the quarter.
  • Moore Capital Management sold 25,000 Legend Biotech shares in Q2 2023, an estimated $1.21M.
  • Moore Capital Management first reported a position in Legend Biotech in Q4 2022 and held it in 2 quarters.
  • Moore Capital Management's Legend Biotech position peaked at $1.21M in Q1 2023.
  • 194 funds tracked by Wall St. Rank held Legend Biotech as of Q2 2023.

Based on Moore Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.